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Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is the leading cause of dementia in the elderly. A recent
positron emission tomography imagingstudy demonstrated upregulatedbrain arachidonic acid (AA) metabolism inAD patients.
Further,amousemodelofADshowsanincreaseinAA-releasingcytosolicphospholipase A2(cPLA2)inbrain,andareductionin
cPLA2 activity ameliorated cognitive deﬁcits. These observations led us to hypothesize that there is an upregulation of AA
cascade and neuroinﬂammatory markers in the brain of AD patients. To test this hypothesis, we measured protein and
mRNA levels of AA cascade, neuroinﬂammatory and synaptic markers in postmortem frontal cortex from 10 AD patients and 10
age-matched controls. Consistent with our hypothesis, AD frontal cortex showed signiﬁcant increases in protein and mRNA
levels ofcPLA2-IVA,secretory sPLA2-IIA, cyclooxygenase-1and-2, membrane prostaglandin (PG) synthase-1 andlipoxygenase-
12 and -15. Calcium-independent iPLA2-VIA and cytosolic PGE2 synthase were decreased. In addition, interleukin-1b, tumor
necrosis factor-a, glial ﬁbrillary acidic protein and CD11b were increased. AD postmortem brain also showed signs of cellular
injury, including decreased synaptophysinand drebrin,pre- andpostsynaptic markers.These resultsindicate that increased AA
cascade and inﬂammatory markers could contribute to AD pathology. Altered brain AA cascade enzymes could be considered
therapeutic targets for future drug development.
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Introduction
The postmortem Alzheimer’s disease (AD) brain is character-
ized by intracellular neuroﬁbrillary tangles with paired helical
ﬁlaments consisting of phosphorylated t-protein, and extra-
cellular senile (neuritic) plaques containing b-amyloid ﬁbrils.
In the United States, nearly 5.3 million people are affected
by AD.
1 Common behavioral disturbances, aside from
memory loss, are apathy, depression, agitation and general
withdrawal. Apathy is the most prevalent disturbance, affect-
ing about 70% of AD patients; depression ranks second,
occurring in about 54% of patients; and agitation ranks third,
appearing in about 50% of patients.
2
The senile plaques often are inﬁltrated by activated
microglia that secrete inﬂammatory cytokines, release nitric
oxide and express peripheral benzodiazepine receptors.
3–6
Inﬂammatory cytokines can activate many brain signaling
pathways, including the arachidonic acid (AA, 20:4n-6)
metabolic cascade.
7 For example, activation of the cytokine
interleukin(IL)-1 receptorcascadecanincreaseexpressionof
AA-metabolizing enzymes, including AA-selective cytosolic
phospholipase A2 (cPLA2), secretory sPLA2
8 and cyclooxy-
genase (COX)-2,
9 and of the transcription factors activator
protein (AP)-2 and/or nuclear factor kappa B that regulate
genetranscriptionoftheseenzymes.Thereleasednitricoxide
can also promote AA hydrolysis from the membrane by
cPLA2, by stimulating glutamate release from nerve terminals
and thereby increasing intracellular Ca
2þ concentrations via
postsynaptic ionotropic N-methyl-D-aspartate and other glu-
tamatergic receptors.
10,11 b-Amyloid peptide can also pro-
voke glutamate-induced excitotoxicity and PLA2 activation.
12
AA is a conditionally essential polyunsaturated fatty acid
found mainly in the stereospeciﬁcally numbered-2 position of
membrane phospholipids, from which it can be hydrolyzed by
cPLA2 or sPLA2. A portion of the released AA is metabolized
to bioactive prostaglandin H2 (PGH2) by COX-1 or COX-2, to
cytoprotective epoxyeicosatrienoic acid by cytochrome p450
epoxygenase, or to cytotoxic leukotrienes by lipoxygenase
(LOX)subtypes-5,-12and-15.
13BioactivePGH2isconverted
to PGE2 (PGE) by membrane PG synthase-1 (mPGES-1) or
cytosolic PG synthase (cPGES). PGH2 also can be converted
to thromboxane A2 by thromboxane synthase (TXS).
14 Of the
two COX isoenzymes, COX-1 is constitutively expressed,
whereas COX-2 is inducible. cPGES uses PGH2 produced by
COX-1, whereas mPGES-1 uses COX-2-derived endo-
peroxide.
15 AA and its metabolites can modulate signal trans-
duction, transcription, neuronal activity, apoptosis and many
other processes within the brain.
16–18
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www.nature.com/tpRecent human imaging and postmortem studies have
demonstrated an elevated AA incorporation coefﬁcient (k*)
as well as altered phospholipid fatty acid concentrations
19 in
brains of AD patients, particularly in regions reported to have
high densities of senile (neuritic) plaques with activated
microglia.
20 An increase in k* is suggestive of increased AA
incorporation and utilization by the brain. AA utilization by the
brain can be initiated by the release of AA from the
phospholipid membrane by cPLA2. Genetic deletion of cPLA2
has been shown to improve cognitive performance in a
transgenic animal model of AD.
21 Moreover, drugs that
decrease turnover and metabolites of the AA cascade, such
as lithium and valproate,
22 have been reported to have
beneﬁcial effects in patients with HIV-associated demen-
tia.
23,24 Further studies have shown beneﬁcial effects
of lithium in AD patients.
25–27 These ﬁndings suggest that
the AA cascade might have a role in the cognitive deﬁcits
associated with dementia.
In view of evidence of excitotoxicity and neuroinﬂammation
in AD,
28,29 and of elevated AA metabolism in AD patients,
20
wehypothesizedthattheAAcascadeisupregulatedintheAD
brain and is accompanied by elevated neuroinﬂammatory
markers as well as by synaptic marker loss. To test this
hypothesis in this study, protein and mRNA levels of AA
cascade enzymes, neuroinﬂammatory markers and synaptic
markers were compared between postmortem frontal cortex
from 10 AD patients and 10 age-matched controls. We also
compared expression of Ca
2þ-independent iPLA2, which is
selective for docosahexaenoic acid (22:6n-3) in membrane
phospholipid.
30 The frontal cortex (Brodmann area 9) was
chosen for study because functional and structural abnorm-
alities have been reported in this region in AD patients.
31–35
Materials and methods
Postmortem brain samples. The protocol was approved by
the Institutional Review Board of McLean Hospital, and by
the Ofﬁce of Human Subjects Research of the National
Institutes of Health (no. 4380). Frozen postmortem human
frontal cortex (Brodmann area 9) from 10 AD patients (diag-
nosed by history and the presence of senile neuritic plaques
and neuroﬁbrillary tangles) and 10 age-matched controls was
provided by the Harvard Brain Tissue Resource Center
(McLean Hospital, Belmont, MA, USA) under PHS grant
number R24MH068855 to JS Rao. Age (years, control:
70.20±2.4 vs AD: 70.60±2.4), postmortem interval (hours,
control: 19.16±1.0 vs AD: 19.74±1.0) and brain pH (control:
6.76±0.07 vs AD: 6.84±0.07) did not differ signiﬁcantly
between the two groups, whereas the AD patients had been
exposed to various psychotropic medications (Table 1).
Preparation of cytosolic fraction. Cytosolic and mem-
brane extracts were prepared from postmortem frontal cortex
of AD and control subjects as reported.
36 Frontal cortex
tissue was homogenized in a homogenizing buffer containing
20mM Tris-HCl (pH 7.4), 2mM EGTA, 5mM EDTA, 1.5mM
pepstatin, 2mM leupeptin, 0.5mM phenylmethylsulfonyl
ﬂuoride, 0.2Uml
 1 aprotinin and 2mM dithiothreitol, using a
Teﬂon homogenizer. The homogenate was centrifuged at
100000g for 60min at 41C. The resulting supernatant-1 was
the cytosolic fraction, and the pellet was resuspended in the
homogenizing buffer containing 0.2% (w/v) Triton X-100. The
suspension was kept at 41C for 60min with occasional stirring
and then centrifuged at 100000g for 60min at 41C. The
resulting supernatant-2 was the membrane fraction. Protein
concentrations in membrane and cytosolic fractions were
determined with Protein Reagent (Bio-Rad, Hercules, CA,
USA). The membrane and cytosolic fractions were conﬁrmed
using speciﬁc markers cadherin and tubulin, respectively.
Western blot analysis. Proteins (50mg) were separated on
4–20% SDS-polyacrylamide gels (Bio-Rad). Following
electrophoresis, the proteins were transferred to a poly-
vinylidene ﬂuoride membrane (Bio-Rad). Protein blots were
incubated overnight in Tris-buffered-saline, containing
5% non-fat dried milk and 0.1% Tween-20, with speciﬁc
primary antibodies (1:200 dilution) for cPLA2-IVA, sPLA2-IIA,
iPLA2-VIA, COX-1 (1:1000), COX-2 (1:500), cytochrome
P450 epoxygenase, TXS, 5-, 12- and 15-LOX (Abcam,
Cambridge, MA, USA) and neuron-speciﬁc enolase
(1:10000) mPGES-1(1:200), cPGES, IL-1beta (IL-1b),
tumor necrosis factor-alpha (TNF-a) CD11b, and glial
ﬁbrillary acidic protein (GFAP). Synaptophysin, drebrin and
mPGES-1 were determined using a speciﬁc (1:200) primary
antibody (Abcam, Cambridge, MA, USA). Cytoplasmic
protein blots were incubated with appropriate horseradish
peroxidase-conjugated secondary antibodies (Bio-Rad) and
were visualized using a chemiluminescence reaction (Kodak,
Rochester, NY, USA). Optical densities of immunoblot bands
were measured using Alpha Innotech Software (Alpha
Innotech, San Leandro, CA, USA) and were normalized to
b-actin (Sigma-Aldrich, St Louis, MO, USA) to correct for
unequal loading. All experiments were carried out twice with
10 control and 10 postmortem brain samples from AD
patients. Values were expressed as percent of control.
Total RNA isolation and real time RT-PCR. Total RNA
was isolated from the frontal cortex using an RNeasy mini kit
(Qiagen, Valencia, CA, USA). RNA integrity number was
measured using a Bioanalyzer (Agilent, Santa Clara, CA,
USA). RNA integrity number values are control 6.80±0.65
and AD 6.85±0.12 (mean±s.e.m). Complementary DNA
was prepared from total RNA using a high-capacity cDNA
Archive kit (Applied Biosystems, Foster City, CA, USA).
mRNA levels (cPLA2-IVA, sPLA2-IIA, iPLA2-VIA, COX-1,
COX-2, m-PGES-1, cPGES, LOX-5, -12, -15, TXS, cyto-
chrome p450 epoxygenase and neuron-speciﬁc enolase)
were measured by quantitative RT-PCR, using an ABI
PRISM 7000 sequence detection system (Applied
Biosystems). Speciﬁc primers and probes for cPLA2-IVA,
sPLA2-IIA, iPLA2-VIA, COX-1, COX-2, mPGES-1, cPGES,
LOX-5, -12, -15, TXS, cytochrome P450 epoxygenase,
IL-1b, TNF-a, CD11b, GFAP, synaptophysin and drebrin
were purchased from TaqMan
s gene expression assays
(Applied Biosystems), and consisted of a 20  mix of un-
labeled PCR primers and Taqman minor groove binder probe
(FAM dye-labeled, Applied Biosystems). The fold-change in
gene expression was determined by the DDCT method.
37
Data are expressed as the relative level of the target gene
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Translational Psychiatry(cPLA2, sPLA2, iPLA2, COX-1, COX-2, m-PGES-1, cPGES,
LOX-5,- 12,- 15, TXS, cytochrome P450 epoxygenase,
IL-1b, TNF-a, CD11b, GFAP, synaptophysin and drebrin)i n
the postmortem AD brain normalized to the endogenous
control (b-globulin) and relative to the control (calibrator),
as previously described.
38 All experiments were carried
out twice in triplicate with 10 controls and 10 postmortem
AD brain samples and data are expressed as relative
expression.
Statistical analysis. Data are expressed as mean±s.e.m.
Statistical signiﬁcance of means was calculated using a two-
tailed unpaired t-test. Pearson correlations were made
between age, postmortem interval and pH of the frontal
cortex, and mRNA levels of sPLA2, iPLA2, COX-1, COX-2,
m-PGES-1, cPGES, LOX-5, -12, -15, TXS, cytochrome P450
epoxygenase, IL-1b, TNF-a, CD11b and GFAP in post-
mortem brain from controls and AD patients, separately.
Statistical signiﬁcance was set at Po0.05.
Results
Upregulated protein and mRNA levels of cPLA2, sPLA2
and COX-2. Mean protein levels of cPLA2-IVA and sPLA2-
IIA were increased signiﬁcantly by 123% (Po0.001) and
87% (Po0.01), respectively (Figures 1a and b), in AD com-
pared with control frontal cortex, whereas the mean iPLA2-
VIA protein level was decreased signiﬁcantly by  30%
(Po0.05) compared with controls (Figure 1c). Mean mRNA
levels of cPLA2-IVA and sPLA2-IIA were increased signi-
ﬁcantly in AD compared with control brain by 4.6-fold
(Po0.01) and by fourfold (Po0.01), respectively (Figures
1d and e), whereas iPLA2-VIA mRNA was signiﬁcantly
decreased by 0.6-fold (Po0.05) (Figure 1f). COX-2 protein
and mRNA levels were increased signiﬁcantly by 79%
(Figure 2a, Po0.01) and threefold (Figure 2c, Po0.01),
respectively, whereas COX-1 protein was signiﬁcantly
increased by 24% (Figure 2b, Po0.05), without a signi-
ﬁcant change of the mRNA level (Figure 2d), in the AD cortex
compared with control.
Increased protein and mRNA levels of mPGES-1.
Statistically signiﬁcant increases were found in mPGES-1
protein (by 82%, Po0.01, Figure 2e) and mRNA levels
(by 3.1-fold, Po0.01, Figure 2g) in AD patients compared
with controls. Mean protein (by 65%, Po0.01, Figure 2f) and
mRNA (by 0.32-fold, Po0.01, Figure 2h) levels of cPGES
were signiﬁcantly decreased in AD patients compared with
controls.
Table 1 Characteristics of control subjects and patients with Alzheimer’s disease
Group Age
(years)
Sex PMI (h) Cause of death Medications Disease
stage
Genotype
Control 60 F 21 Cardiopulmonary attack Aspirin ApoE2/4/
ApoE2/3
Control 80 M 15 Myocardial infarction Furosemide ApoE2/4
ApoE2/3
Control 79 F 19 Cardiopulmonary attack Isosorbide ApoE2/4
ApoE2/3
Control 72 M 22 Cardiopulmonary attack Atorvastatin ApoE2/4
ApoE2/3
Control 64 M 15 Acute myocardial
infarction
Vitamins ApoE2/4
ApoE2/3
Control 74 M 18 Cardiac arrest Atenolol and digoxin ApoE2/4
ApoE2/3
Control 61 M 22 Myocardial infarction Vitamins ApoE2/4
ApoE2/3
Control 78 F 17 Myocardial infarction Atorvastatin ApoE2/4
ApoE2/3
Control 63 M 15 Heart failure Furosemide ApoE2/4
ApoE2/3
Control 71 M 23 Cardiac arrest Aspirin ApoE2/4
ApoE2/3
AD 76 F 25 Stroke Sertraline, carbamazepine, alendronate and aspirin V ApoE4/4
AD 83 M 17 Stroke Donepezil, valproate, tamsulosin and escitalopram V ApoE4/4
AD 72 M 24 AD Atenolol, donepezil, valproate and alprazolam VI ApoE4/4
AD 78 F 17 AD Fexofenadine, donepezil and aspirin VI ApoE4/4
AD 75 M 15 Atherosclerosis Gabapentin, furosemide, quetiapine and
escitalopram
VI ApoE2/4
ApoE2/3
AD 66 M 23 Broken hip and AD Rivastigmine and donepezil V ApoE2/4
ApoE2/3
AD 63 M 18 Pneumonia Carbamazepine, sertraline, aspirin and quetiapine VI ApoE2/4
ApoE2/3
AD 71 M 16 End of AD Atorvastatin, donepezil, pantoprazole, verapamil,
vitamin E and risperidone
VI ApoE2/4
ApoE2/3
AD 61 F 21 End of AD Pantoprazole, verapamil, vitamin E and risperidone VI ApoE2/4
ApoE2/3
AD 61 M 17 Pneumonia Valproate, quetiapine and olanzapine VI Not available
Abbreviations: AD, Alzheimer’s disease; F, female; M, male; PMI, postmortem interval.
Not available, sample volume was not enough for this experiment; staging was done according to Reisberg et al.
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Mean protein levels of 12- and 15-LOX were increased signi-
ﬁcantly by 82% (Po0.01) and 35% (Po0.01), respectively,
(Figures 3b and c), in AD compared with control frontal
cortex, whereas the mean 5-LOX protein level was not signi-
ﬁcantly altered between groups (Figure 3a). Mean mRNA
Figure 1 Mean cPLA2 (a), sPLA2(b) andiPLA2 (c) protein (with representative immunoblots) as percent of controlin frontalcortex,from control(n¼10) andAD (n¼10)
subjects.Dataareopticaldensitiesrelativetothatofb-actin.MeanmRNAaspercentofcontrolofcPLA2(d),sPLA2(e)andiPLA2(f)infrontalcortexfromcontrol(n¼10)and
AD (n¼10) subjects, measured using RT-PCR. Data are normalized to the endogenous control (b-globulin) and expressed relative to the control (calibrator), using the
DDCT method. Mean±s.e.m., *Po0.05, **Po0.01 and ***Po0.001.
Figure 2 Mean COX-2 (a), COX-1 (b), mPGES-1 (e) and cPGES-2 (f) protein (with representative immunoblots) as percent of control in frontal cortex, from control
(n¼10) and AD (n¼10) subjects. Data are optical densities with relative to that of b-actin. COX-2 (c), COX-1 (d) mPGES-1 (g) and cPGES-2 (h) mRNA levels in the frontal
cortex from controls (n¼10) and AD patients (n¼10), measured using RT-PCR. Data are normalized to the endogenous control (b-globulin) and expressed with relative to
the control (calibrator), using the DDCT method. Mean±s.e.m., *Po0.05 and **Po0.01.
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compared with control brain by threefold (Po0.01) and 2.6-fold
(Po0.05), respectively (Figures 3f and g), whereas 5-LOX
mRNA was not signiﬁcantly changed (P40.05, Figure 3e).
Mean protein and mRNA levels of TXS did not differ
signiﬁcantly between AD and control brain (data not shown).
Mean protein (36%) and mRNA (0.5-fold) levels of P450
epoxygenase were signiﬁcantly reduced in AD brains com-
pared with controls (Figures 3d and h).
Increased proinﬂammatory cytokines and markers of
astrocytes and glia. Postmortem AD brains showed
signiﬁcantly elevated brain protein levels of inﬂammatory
cytokines IL-1b (3.3-fold) and TNF-a (2.06-fold) compared
with controls (Figures 4a and b). These elevations corres-
ponded to signiﬁcantly increased mRNA levels of IL-1b
(1.94-fold) and TNF-a (1.6-fold) (Figures 4c and d),
respectively. Markers of astrocytes and glia, such as GFAP
protein (149%) and mRNA (2.89-fold), as well as the
microglial markers CD11B protein (150%) and mRNA
(1.79-fold) were upregulated in postmortem AD brain
(Figures 4e and f).
Indications of cellular damage and loss. Protein and
mRNA levels of synaptophysin and drebrin were decreased
signiﬁcantly in postmortem frontal cortex from AD brain
relative to control (Figures 5a–d). Mean protein and mRNA
levels of neuron-speciﬁc enolase did not differ signiﬁcantly
between AD and control brain (data not shown).
Correlations with brain variables. Pearson correlations
between the protein and mRNA levels in AD brain treated
separately on the one hand, and postmortem interval, age
and pH on the other, were all statistically insigniﬁcant
(P40.05) (Table 2). Mean values of the three parameters
did not differ signiﬁcantly between AD and control groups.
Discussion
Frontal cortex from postmortem AD patients showed upregu-
lated neuroinﬂammatory markers accompanied by disturbed
AA cascade markers. The proinﬂammatory cytokines, IL-1b
andTNF-a,wereincreased,aswerethemicroglialcellmarker,
CD11b and the astrocytic marker GFAP. Synaptophysin and
drebrin, pre- and postsynaptic markers, were signiﬁcantly
decreased in AD brain. Together, these data support a role
for upregulated AA metabolism and cytokine production in
association with neuronal damage in the AD brain.
Consistent with increased brain AA incorporation in AD
patients,
20 postmortem frontal cortex showed increased
protein and mRNA levels of cPLA2-IVA compared with
controls. Similar observations were reported in cerebral
Figure 3 Mean 5-LOX (a), 12-LOX (b) 15-LOX (c) and p450 epoxygenase (d) protein levels (with representative immunoblots) in frontal cortex from control (n¼10) and
AD (n¼10) subjects. Bar graphs are ratios of optical densities of LOXs and p450 epoxygenase to that of b-actin, expressed as percent of control. 5-LOX (e), 12-LOX (f) 15-
LOX(g)andp450epoxygenase(h)mRNAlevelsinpostmortemfrontalcortexfromthecontrol(n¼10)andbipolardisorder(n¼10)subjects,measuredusingRT-PCR.Data
are levels of LOXs and p450 epoxygenase in AD normalized to the endogenous control (b-globulin) and relative to the control (calibrator), using the DDCT method.
Mean±s.e.m., *Po0.05, **Po0.01, ***Po0.001.
Altered AA cascade enzymes in Alzheimer disease
JS Rao et al
5
Translational Psychiatrycortex
39 and hippocampal regions of postmortem AD brain.
40
This increase could result from the presence of amyloid b.A n
earlier in vitro study demonstrated that treatment with low
concentrations of soluble amyloid b (1–40) or amyloid b
(1–42) peptide of rat cortical neurons resulted in an early
calcium-dependent release of AA associated with a transient
Figure 4 Mean IL-1b (a), TNF-a (b), GFAP (c) and CD11B (d) protein levels (with representative immunoblots) in frontal cortex from control (n¼10) and AD (n¼10)
subjects. Bar graphs are ratios of optical densities of IL-1b, TNF-a, GFAP and CD11B that of b-actin, expressed as percent of control. IL-1b (e), TNF-a (f), GFAP (g) and
CD11B (h) mRNA levels in postmortem frontal cortex from the control (n¼10) and AD (n¼10) subjects, measured using RT-PCR. Data are levels of IL-1b, TNF-a, GFAP
and CD11B in AD normalized to the endogenous control (b-globulin) and relative to the control (calibrator), using the DDCT method. Mean±s.e.m., *Po0.05, **Po0.01,
***Po0.001.
Figure5 Meansynaptophysin(a)anddrebrin(b)protein(withrepresentativeimmunoblots)incontrol(n¼10)andAD(n¼10)frontalcortex.Dataareopticaldensitiesof
synaptophysinanddrebrinproteinstob-actin,expressedaspercentofcontrol.mRNAlevelsofsynaptophysinanddrebrin(c)inpostmortemcontrol(n¼10)andAD(n¼10)
frontal cortex, measured using RT-PCR. Data are levels of synaptophysin and drebrin in the AD patients normalized to the endogenous control (b-globulin) and relative to
control level (calibrator), using the DDCT method. Mean±s.e.m. and *Po0.05, ***Po0.001.
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41 Another calcium-dependent
AA-releasing enzyme sPLA2 was also increased in post-
mortem AD brain. An increase also was reported in
postmortem hippocampus and in cerebrospinal ﬂuid from
AD patients.
42,43 Again this could result from the presence
of b-amyloid peptide in the AD brain.
12 Frontal cortex
calcium-independent iPLA2-VIA protein and mRNA levels
were signiﬁcantly decreased in the AD brain. This enzyme will
release another important n-3 polyunsaturated fatty acid,
docosahexaenoic acid, from membrane phospholipid. Similar
dysregulation of iPLA2 was seen in n-3 polyunsaturated fatty
acid-deprived rats as well as in iPLA2 knockout mice.
44,45
A signiﬁcant decrease in iPLA2 expression in AD might
have relevance to the report of a mutated iPLA2 gene in
neurodegenerative disorders.
46
AAismetabolizedtoPGH2byCOX-1andCOX-2. COX-1is
constitutive, whereas COX-2 is an inducible enzyme. Protein
levels of both enzymes were signiﬁcantly increased in AD
brain without a signiﬁcant change in COX-1 mRNA. PGH2 is
further metabolized to PGE2 by mPGES and cPGES. Protein
and mRNA levels of mPGES were signiﬁcantly increased with
signiﬁcant decreases in cPGES protein and mRNA levels
in the AD brain. Consistent with these ﬁndings, studies have
demonstrated increased hippocampal COX-1 and frontal
cortex COX-2levels in the ADbrain.
47 The productofmPGES
enzyme,PGE2,wasalsoreportedtoincreaseincerebrospinal
ﬂuid from AD patients.
48 These changes could arise from the
presenceofb-amyloidpeptideinthebrain.
49–51Arecentstudy
alsoindicatesreducedimmunoreactivitytothePGtransporter
in postmortem frontal cortex of AD patients.
52 These changes
could lead to an increased proinﬂammatory product PGE2.
AA is also channeled to other bioactive metabolites by
LOXs such as 5-, 12- and 15-LOX. The protein and mRNA
levels of LOXs 12 and 15 (type 1) were signiﬁcantly increased
in AD brain. Consistent with this observation, the postmortem
AD brain showed elevated immunoreactivity to LOX12/15 and
levels of 12/15-hydroxyeicosatetraenoic acids, metabolic
products of 12/15-LOX in frontal cortex and temporal
regions.
53 These increases directly correlated with brain lipid
peroxidation.
53 Frontal cortex 5-LOX was not changed
signiﬁcantly in AD brain compared with control. In contrast,
a reduced hippocampal 5-LOX immunoreactivity was
reported in AD brain.
54 This discrepancy might be related to
regional differences. The other AA cascade markers, protein
and mRNA levels of TXS, were not signiﬁcantly changed
in postmortem AD brain. The protein and mRNA levels of
cytochrome p450 epoxygenase were signiﬁcantly reduced
in AD brain compared with control. Given that epoxyeicosa-
trienoic acid produced by this enzyme can be neuro-
protective,
55,56 the reduced brain protein and mRNA levels
of cytochrome p450 epoxygenase in AD may reﬂect a loss of
neuroprotective processes.
The increase in AA cascade markers could result from
increase in proinﬂammatory cytokines including IL-1b and
TNF-a. This notion, based on studies that b-amyloid may
cause AA release by stimulating microglia, could have led
to the secretion of IL-1b and TNF-a,
57,58 and secondary
increased transcription of cPLA2-IVA, sPLA2-IIA, and COX-2.
Cell culture studies have shown that both IL-1b and TNF-a
can induce transcription of cPLA2, sPLA2 and COX-2 genes
in a nuclear factor-kappa B-dependent manner,
59–62 as
nuclear factor-kappa B binding sites are present on the
promoter regions of these genes.
63–65
AD brain shows decreases in drebrin protein and mRNA
levels compared with controls. The decreased protein and
mRNA levels of the postsynaptic marker, drebrin, suggest
synaptic loss, and studies indicate an association between
lower brain drebrin levels and an increased risk of dementia in
humans,
66–69 including patients with AD.
70 Similarly, drebrin
is decreased in other psychiatric illnesses such as bipolar
disorder and schizophrenia, in which neurocognitive impair-
ments are common.
71
Elevated IL-1b and TNF-a levels and increased expres-
sion of AA cascade enzymes have been implicated in the
initiation of neuronal damage,
16 contributing to cognitive–
behavioral impairment in AD. A transgenic mouse model
of AD showed elevated levels of cPLA2, and cPLA2 inhibition
or deletion improved cognitive performance.
21 These obser-
vations support the notion that selective inhibition of neuro-
inﬂammatory and AA cascade pathways may alleviate
Table 2 Probabilities and Pearson correlation between brain protein and
mRNA levels and subject age, postmortem intervals and pH
Age PMI pH
P-value R2 P-value R2 P-value R2
Protein
cPLA2 0.589 0.02 0.617 0.0142 0.151 0.111
sPLA2 0.152 0.11 0.856 0.0019 0.238 0.076
iPLA2 0.812 0.00 0.779 0.0045 0.180 0.097
COX-1 0.417 0.04 0.673 0.0101 0.163 0.105
COX-2 0.498 0.03 0.409 0.0381 0.728 0.007
mPGES 0.892 0.00 0.253 0.0718 0.367 0.045
cPGES 0.768 0.00 0.938 0.0003 0.125 0.126
12-LOX 0.089 0.00 0.914 0.0010 0.613 0.022
15-LOX 0.640 0.01 0.443 0.0350 0.139 0.124
p450 Epoxy 0.091 0.15 0.997 0.0000 0.235 0.077
TNF-a 0.432 0.03 0.341 0.0505 0.243 0.096
IL-1b 0.988 0.00 0.881 0.0013 0.898 0.001
Cd11b 0.998 0.00 0.828 0.0027 0.879 0.001
GFAP 0.357 0.05 0.277 0.0733 0.979 0.000
SYP 0.572 0.02 0.345 0.0497 0.845 0.002
Drebrin 0.323 0.05 0.545 0.0208 0.203 0.089
mRNA
cPLA2 0.800 0.00 0.120 0.120 0.520 0.027
sPLA2 0.120 0.12 0.790 0.000 0.410 0.030
iPLA2 0.270 0.06 0.180 0.090 0.100 0.130
COX-1 0.960 0.00 0.460 0.020 0.610 0.010
COX-2 0.330 0.05 0.300 0.050 0.070 0.160
mPGES 0.900 0.00 0.380 0.042 0.700 0.000
cPGES 0.350 0.04 0.880 0.000 0.190 0.090
12-LOX 0.350 0.04 0.200 0.080 0.190 0.090
15-LOX 0.490 0.02 0.420 0.030 0.690 0.000
p450 Epoxy 0.430 0.03 0.410 0.030 0.960 0.000
TNF-a 0.780 0.00 0.340 0.050 0.150 0.110
IL-1b 0.310 0.09 0.950 0.000 0.580 0.020
Cd11b 0.620 0.01 0.790 0.000 0.860 0.004
GFAP 0.350 0.05 0.270 0.070 0.970 0.000
SYP 0.810 0.00 0.730 0.000 0.650 0.010
Drebrin 0.170 0.16 0.630 0.020 0.750 0.000
Abbreviations: COX, cyclooxygenase; cPGES, cytosolic prostaglandin
synthase; cPLA2, cytosolic phospholipase A2, GFAP, glial ﬁbrillary acidic
protein; iPLA, calcium-independent phospholipase A2, LOX, lipoxygenase;
mPGES, membrane prostaglandin synthase; p450 epoxy, cytochrome p450
epoxygenase; sPLA2, secretory phospholipase A2; TNF-a, tumor necrosis
factor-alpha; SYP, synaptophysin.
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Translational Psychiatrycognitive impairment. Some clinical studies indicate that
mood stabilizers such as lithium and sodium valproate
are beneﬁcial in HIV-1-associated dementia patients,
23,24
and both of these agents attenuated neuroinﬂammation-
and N-methyl-D-aspartate-induced upregulated AA cascade
markers in rat brain.
10,72,73 A preliminary imaging study
shows that AA metabolism is widely elevated in the AD brain,
particularly in regions reported to have high densities of senile
(neuritic) plaques with activated microglia. To the extent that
the elevations represent upregulated AA metabolism asso-
ciated with neuroinﬂammation, positron emission tomography
with 1-(11)C-AA could be used to examine neuroinﬂammation
in patients with AD and other brain diseases.
20,74 If correct, an
increased AA image would be a biological marker of disease
progression and could be used to evaluate therapeutic
efﬁcacy.
The AA cascade changes in the AD brain partly overlap
changes reported in postmortem brain of bipolar disorder
patients, in which excitotoxicity and neuroinﬂammation are
considered to have a role.
75 In bipolar disorder, brain cPLA2,
sPLA2 and COX-2 expression are upregulated.
75 Thus, the
changes noted here may not be speciﬁc to AD, but be more
generally related to excitotoxic and inﬂammatory processes
that occur in multiple chronic and progressive neurodegene-
rative and neuropsychiatric disorders.
Pearson correlation showed that no mRNA or protein level
in either AD or control brains was correlated signiﬁcantly with
postmortem interval, brain pH or age of the subject, and mean
values of these parameters did not differ signiﬁcantly between
the two groups. However, future studies should examine AA
cascademarkersin brains from patientswith schizophreniaor
with unipolar depression or Parkinson’s disease to test for
disease speciﬁcity.
In conclusion, AD brain showed upregulated neuroinﬂam-
matory and AA cascade markers associated with loss of
synaptic markers, which may have a role in cognitive
impairment and progression of AD disease. The attenuation
of AA cascade-induced pathways may be a strategy to treat
AD patients.
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